CNS Pharmaceuticals, Inc. (CNSP)
Oxford Ledge is still expanding full research coverage of CNSP. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
CNS Pharmaceuticals develops neurology and oncology therapies, recently shifting strategy to build a diversified pipeline of clinical and preclinical assets.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-07-02
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Entry into material agreement; 3.02; Departure/election of directors or officers; Financial statements and exhibits 2026-05-04
- 10-K/A Amended annual report 2026-04-30
- 10-K Annual financial report with audited statements 2026-03-31
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for CNSP. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open CNSP in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.